Literature DB >> 22093502

A micro-ribonucleic acid signature associated with recovery from assist device support in 2 groups of patients with severe heart failure.

Ravi Ramani1, Deborah Vela, Ana Segura, Dennis McNamara, Bonnie Lemster, Vishnupriya Samarendra, Robert Kormos, Yoshiya Toyoda, Christian Bermudez, O H Frazier, Christine S Moravec, John Gorcsan, Heinrich Taegtmeyer, Charles F McTiernan.   

Abstract

OBJECTIVES: This study was conducted to test the hypothesis that cardiac micro-ribonucleic acid (miR) profiling in severe heart failure patients at the time of ventricular assist device (VAD) placement would differentiate those who remained VAD-dependent from those with subsequent left ventricular (LV) recovery.
BACKGROUND: The relationship of myocardial miR expression to ventricular recovery is unknown.
METHODS: We studied 28 patients with nonischemic cardiomyopathy requiring VAD support consisting of test and validation cohorts from 2 institutions: 14 with subsequent LV recovery and VAD removal and 14 clinically matched VAD-dependent patients. Apical core myocardium was studied for expression of 376 miRs by polymerase chain reaction (PCR) array and real-time-PCR methods. Samples from 7 nonfailing hearts were used in confirmatory studies.
RESULTS: By PCR array, 10 miRs were differentially expressed between LV recovery and VAD-dependent patients in the test cohort. The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent). The LV recovery patients also had significantly smaller cardiomyocytes by quantitative histology in both cohorts.
CONCLUSIONS: Lower cardiac expression of miRs 23a and 195 and smaller cardiomyocyte size at the time of VAD placement were associated with subsequent LV functional recovery. Differential expression of miRs at VAD placement may provide markers to assess recovery potential.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22093502      PMCID: PMC3226759          DOI: 10.1016/j.jacc.2011.08.041

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  36 in total

1.  Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices.

Authors:  Michael Dandel; Yuguo Weng; Henryk Siniawski; Evgenij Potapov; Hans B Lehmkuhl; Roland Hetzer
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

Review 2.  MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets.

Authors:  Eva van Rooij; Eric N Olson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

3.  Regression of cellular hypertrophy after left ventricular assist device support.

Authors:  A Zafeiridis; V Jeevanandam; S R Houser; K B Margulies
Journal:  Circulation       Date:  1998-08-18       Impact factor: 29.690

4.  Control of stress-dependent cardiac growth and gene expression by a microRNA.

Authors:  Eva van Rooij; Lillian B Sutherland; Xiaoxia Qi; James A Richardson; Joseph Hill; Eric N Olson
Journal:  Science       Date:  2007-03-22       Impact factor: 47.728

5.  The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2.

Authors:  Baofeng Yang; Huixian Lin; Jiening Xiao; Yanjie Lu; Xiaobin Luo; Baoxin Li; Ying Zhang; Chaoqian Xu; Yunlong Bai; Huizhen Wang; Guohao Chen; Zhiguo Wang
Journal:  Nat Med       Date:  2007-04-01       Impact factor: 53.440

6.  Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy.

Authors:  Jennifer L Hall; Emma J Birks; Suzanne Grindle; Martin E Cullen; Paul J Barton; James E Rider; Sangjin Lee; Subash Harwalker; Ami Mariash; Neeta Adhikari; Nathan J Charles; Leanne E Felkin; Sean Polster; Robert S George; Leslie W Miller; Magdi H Yacoub
Journal:  Eur Heart J       Date:  2006-11-28       Impact factor: 29.983

7.  A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure.

Authors:  Eva van Rooij; Lillian B Sutherland; Ning Liu; Andrew H Williams; John McAnally; Robert D Gerard; James A Richardson; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-15       Impact factor: 11.205

8.  MicroRNA-133 controls cardiac hypertrophy.

Authors:  Alessandra Carè; Daniele Catalucci; Federica Felicetti; Désirée Bonci; Antonio Addario; Paolo Gallo; Marie-Louise Bang; Patrizia Segnalini; Yusu Gu; Nancy D Dalton; Leonardo Elia; Michael V G Latronico; Morten Høydal; Camillo Autore; Matteo A Russo; Gerald W Dorn; Oyvind Ellingsen; Pilar Ruiz-Lozano; Kirk L Peterson; Carlo M Croce; Cesare Peschle; Gianluigi Condorelli
Journal:  Nat Med       Date:  2007-04-29       Impact factor: 53.440

9.  MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?

Authors:  Yunhui Cheng; Ruirui Ji; Junming Yue; Jian Yang; Xiaojun Liu; He Chen; David B Dean; Chunxiang Zhang
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

10.  Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure.

Authors:  K Dipla; J A Mattiello; V Jeevanandam; S R Houser; K B Margulies
Journal:  Circulation       Date:  1998-06-16       Impact factor: 29.690

View more
  20 in total

1.  Bridge to recovery: understanding the disconnect between clinical and biological outcomes.

Authors:  Stavros G Drakos; Abdallah G Kfoury; Josef Stehlik; Craig H Selzman; Bruce B Reid; John V Terrovitis; John N Nanas; Dean Y Li
Journal:  Circulation       Date:  2012-07-10       Impact factor: 29.690

2.  Cellular, molecular, genomic changes occurring in the heart under mechanical circulatory support.

Authors:  Michele Gallo; Vincenzo Tarzia; Laura Iop; Jonida Bejko; Giacomo Bortolussi; Roberto Bianco; Tomaso Bottio; Gino Gerosa
Journal:  Ann Cardiothorac Surg       Date:  2014-09

3.  Heart failure in remission for more than 13 years after removal of a left ventricular assist device.

Authors:  Ana Maria Segura; Lamia Dris; Edward K Massin; Fred J Clubb; L Maximilian Buja; O H Frazier; Heinrich Taegtmeyer
Journal:  Tex Heart Inst J       Date:  2014-08-01

Review 4.  Reverse remodelling and myocardial recovery in heart failure.

Authors:  Gene H Kim; Nir Uriel; Daniel Burkhoff
Journal:  Nat Rev Cardiol       Date:  2017-09-21       Impact factor: 32.419

5.  MicroRNAs Associated With Reverse Left Ventricular Remodeling in Humans Identify Pathways of Heart Failure Progression.

Authors:  Ravi Shah; Olivia Ziegler; Ashish Yeri; Xiaojun Liu; Venkatesh Murthy; Dustin Rabideau; Chun Yang Xiao; Kristina Hanspers; Arianna Belcher; Michael Tackett; Anthony Rosenzweig; Alexander R Pico; James L Januzzi; Saumya Das
Journal:  Circ Heart Fail       Date:  2018-02       Impact factor: 8.790

6.  Advancing the Science of Myocardial Recovery with Mechanical Circulatory Support: A Working Group of the National, Heart, Lung, and Blood Institute.

Authors:  Stavros G Drakos; Francis D Pagani; Martha S Lundberg; J Timothy Baldwin
Journal:  ASAIO J       Date:  2017 Jul/Aug       Impact factor: 2.872

7.  Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes.

Authors:  Anupam Basuray; Benjamin French; Bonnie Ky; Esther Vorovich; Caroline Olt; Nancy K Sweitzer; Thomas P Cappola; James C Fang
Journal:  Circulation       Date:  2014-05-05       Impact factor: 29.690

8.  Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support.

Authors:  Kai-Chien Yang; Kathryn A Yamada; Akshar Y Patel; Veli K Topkara; Isaac George; Faisal H Cheema; Gregory A Ewald; Douglas L Mann; Jeanne M Nerbonne
Journal:  Circulation       Date:  2014-01-15       Impact factor: 29.690

Review 9.  MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential.

Authors:  Palak Shah; Michael R Bristow; J David Port
Journal:  Curr Heart Fail Rep       Date:  2017-12

Review 10.  Role of microRNA in metabolic shift during heart failure.

Authors:  Mark V Pinti; Quincy A Hathaway; John M Hollander
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-10-14       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.